Novel Technology Maps Single-Cell DNA-Protein Interactions

Why It Matters

By enabling precise, single‑cell maps of regulatory protein binding, D&D‑seq accelerates discovery of disease mechanisms and supports development of therapies targeting transcription factors.

Key Takeaways

• D&D‑seq records protein‑DNA contacts using antibody‑linked deaminase.
• Works with standard single‑cell multi‑omics pipelines, no platform redesign.
• Detects weak or transient binding events missed by prior methods.
• Revealed how a leukemia mutation reshapes transcription‑factor binding in blood cells.
• Researchers aim to commercialize the plug‑and‑play technology soon.

Pulse Analysis

The ability to pinpoint where transcription factors and other regulatory proteins bind DNA has long been a bottleneck in functional genomics. Conventional techniques such as ChIP‑seq require large cell populations, struggle with low‑affinity interactions, and cannot be readily combined with single‑cell readouts. The June 2026 Cell paper from Weill Cornell Medicine and the New York Genome Center introduces D&D‑seq, a single‑cell assay that couples an antibody‑directed deaminase to the protein of interest. This simple “dock‑and‑deaminate” step leaves a permanent nucleotide mark that can be captured during routine sequencing, opening a new window on the regulome at cellular resolution.

Beyond its conceptual elegance, D&D‑seq is engineered for compatibility with existing high‑throughput platforms. Researchers can add the antibody‑deaminase cocktail to standard droplet‑based or combinatorial indexing workflows without redesigning hardware or software, enabling simultaneous measurement of the genome, transcriptome, epigenome and now the protein‑DNA interaction layer. Because the deamination signal persists even after fleeting contacts, the method detects weak or transient binding events that escape ChIP‑seq detection. Early experiments mapped the binding landscape of a key hematopoietic transcription factor in normal and mutant blood cells, exposing mutation‑driven regulatory rewiring.

The commercial potential of D&D‑seq is immediate. By delivering a plug‑and‑play module for multi‑omics studies, the technology promises to accelerate drug discovery programs that target transcription factors, a class historically deemed “undruggable.” Clinicians could eventually profile patient‑specific regulomes to predict response to epigenetic therapies or to monitor disease progression at unprecedented granularity. The authors are already training external labs and pursuing a startup route, suggesting that D&D‑seq may become a standard component of the single‑cell toolbox within the next few years.